Background Paliperidone is an active metabolite of risperidone, both of which are antipsychotic agents for treatment of schizophrenia and related psychotic disorders. Pharmacogenetic studies have revealed that the efficacy and side effects of antipsychotic agents are related to polymorphisms of specific genes, however, there are just a few related studies on paliperidone. The current study aims to evaluate whether pharmacogenetic markers related to risperidone and genetic markers associated with schizophrenia have effects on the clinical effectiveness of paliperidone treatment. The study also uses changes of event-related potentials (ERP) as indices for clinical efficacy. Methods It is a prospective, open-label, non-randomized and uncontrolled clinical trial to study the efficacy and side effects of 6-week paliperidone ER treatment for patients with schizophrenia or schizoaffective disorder. The first three weeks of treatment has to be inpatient treatment. In the first two weeks, participants will take 9 mg paliperidone ER daily. Then the dose of paliperidone can be adjusted to within the range of 6-12 mg per day. Efficacy indicators include symptom severity, global functioning, and ERP. Side effect indicators include common side effect evaluate, extrapyramidal symptoms, metabolic profiles, hormonal change, and bone metabolism indices. Participants will also receive examinations for blood drug concentration, genetic polymorphisms, and epigenetic markers.

NCT02433717

Conditions

1. Schizophrenia
2. Schizoaffective Disorder

Interventions

1. Drug: Paliperidone ER

MeSH:Schizophrenia Psychotic Disorders

HPO:Psychosis Schizophrenia

Whether Ser9Gly of the DRD3 gene is associated with the clinical response rate on day 42.. Pharmacogenetic factor on response rate: DRD2. --- Ser9Gly ---

Blood sampling on day 0 (40 ml), day 14 (15 ml) and day 42 (40 ml): 1. Blood paliperidone concentration and pharmacodynamics of risperidone and paliperidone on day 0, day 14, and day 42. 2. Blood biochemistry study (AC sugar, uric acid, cholesterol, triglyceride, HDL-cholesterol, leptin, adiponectin, prolactin) on day 0, day 14, and day 42. 3. Bone turnover markers (serum alkaline phosphatase, calcium, phosphate bone-specific alkaline phosphatase, intact osteocalcin), and hormonal markers (oestradiol, progesterone, LH, FSH and testosterone) on day 0 and day 42. 4. DNA sample for genetic markers on day 0: 1236C/T of the ABCB1 gene, Ser9Gly of the DRD3 gene, Ser311Cys of the DRD2 gene, 267T/C of the 5HTR6 gene, 102T/C of the 5HTR2A gene, 995G/A of the 5HTR2C gene, dinucleotide repeat (GT)n of the BDNF gene, val108/158Met of the COMT gene, and polymorphisms of the RGS4 gene. 5. Epigenetic markers on day 0 and day 42. --- Ser9Gly ---